Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation-Reference-Cited by-同舟云学术

Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

Published:2018-04-17 Issue:6 Volume:48 Page:e12929
ISSN:0014-2972
Container-title:European Journal of Clinical Investigation
language:en
Short-container-title:Eur J Clin Invest

Author:

Serna María José¹,Rivera-Caravaca José Miguel¹^ORCID,Gonzalez-Conejero Rocío²,Esteve-Pastor María Asunción³^ORCID,Valdés Mariano³,Vicente Vicente¹²,Lip Gregory Y.H.⁴⁵,Roldán Vanessa¹,Marín Francisco³

Affiliation:

1. Department of Hematology and Clinical Oncology; Hospital General Universitario Morales Meseguer; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca); Murcia Spain

2. Centro Regional de Hemodonación; Universidad de Murcia; CIBERER; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca); Murcia Spain

3. Department of Cardiology; Hospital Clínico Universitario Virgen de la Arrixaca; Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca); CIBER-CV; Murcia Spain

4. Institute of Cardiovascular Sciences; University of Birmingham; Birmingham UK

5. Aalborg Thrombosis Research Unit; Department of Clinical Medicine; Aalborg University; Aalborg Denmark

Funder

Fundación para la Formación e Investigación Sanitarias de la Región de Murcia

IMIB

Instituto de Salud Carlos III

Sociedad Española de Trombosis y Hemostasia

Fundación Séneca

Publisher

Wiley

Subject

Clinical Biochemistry,Biochemistry,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/eci.12929/fullpdf

Reference37 articles.

1. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment;Cerezo-Manchado;Pharmacogenomics,2014

2. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review;Wan;Circ Cardiovasc Qual Outcomes,2008

3. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey;Pisters;Chest,2010

4. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation *Developed with the special contribution of the European Heart Rhythm Association;Camm;Eur Heart J,2012

5. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy;Perez-Andreu;Blood,2009

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing Warfarin use in Egyptian patients with Autoimmune Diseases – Genetic and Clinical Related Factors;Research Journal of Pharmacy and Technology;2024-02-20

2. Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation;Mayo Clinic Proceedings;2023-05

3. A Systematic Review of Polygenic Models for Predicting Drug Outcomes;Journal of Personalized Medicine;2022-08-27

4. Genotype‐guided warfarin therapy: Still of only questionable value two decades on;Journal of Clinical Pharmacy and Therapeutics;2020-03-13

5. Genetic and Molecular Testing in Thrombosis and Hemostasis: Informing Surveillance, Treatment, and Prognosis;Seminars in Thrombosis and Hemostasis;2019-04-30